Hollis, Robert L. http://orcid.org/0000-0002-1390-3298
Stanley, Barbara
Thomson, John P.
Churchman, Michael
Croy, Ian
Rye, Tzyvia
Bartos, Clare
Nussey, Fiona
Mackean, Melanie
Meynert, Alison M.
Semple, Colin A.
Gourley, Charlie
Herrington, C. Simon http://orcid.org/0000-0001-9177-8165
Funding for this research was provided by:
RCUK | Medical Research Council (I171113-1019)
Target Ovarian Cancer
University of Edinburgh (Oncology Endowment Fund)
Article History
Received: 23 November 2020
Accepted: 13 May 2021
First Online: 2 June 2021
Competing interests
: R.L.H.: consultancy fees from GlaxoSmithKline. F.N.: non-personal interests in Tesaro and AstraZeneca. M.M.: honoraria from Tesaro, BristolMyersSquibb and Roche. C.G.: research funding from Aprea, AstraZeneca, Novartis, Nucana and Tesaro, honoraria/consultancy fees from AstraZeneca, Clovis, GlaxoSmithKline, Core2Ed, Foundation One, MSD, Nucana, Roche, Sierra Oncology and Tesaro, named on issued/pending patents related to predicting treatment response in ovarian cancer beyond the scope of the work described here. B.S., J.P.T., M.C., I.C., T.R., C.B., A.M.M., C.A.S., and C.S.H. declare no competing interest.